Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene exprssion at single cell level in patients broncoalveolar lavage (BAL) cells stimulated ex vivo with bacterial lysate OM-85

ABSTRACT: Gene exprssion at single cell level in patients broncoalveolar lavage (BAL) cells stimulated ex vivo with bacterial lysate OM-85

PROVIDER: PRJNA1086544 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR28293328.fastq.gz	Fastqsanger.gz
	SRR28293329.fastq.gz	Fastqsanger.gz
	SRR28293330.fastq.gz	Fastqsanger.gz
	SRR28293331.fastq.gz	Fastqsanger.gz
	SRR28293332.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Gene exprssion at single cell level in patients broncoalveolar lavage (BAL) cells stimulated ex vivo with bacterial lysate OM-85

Project description:OM-85 is a bacterial lysate used in clinical practice to reduce duration and frequency of recurrent respiratory tract infections. Whereas knowledge on its regulatory effects in vivo has substantially advanced, the mechanisms of OM-85 sensing remain inadequately addressed.The purpose of this study was to investigate the transptomic profile of human airway immune cells in the BAL after ex vivo stimulation with OM-85 at the single cell level and determine to what extent OM-85-induced gene signature in different myeloid cell subsets is dependent on TLR2/TLR4 expression.

2024-03-16 | GSE261353 | GEO

Gene expression profile of human mono-derived DCs stimulated with the bacterial lysate OM-85

Project description:OM-85 is a bacterial lysate used in clinical practice to reduce duration and frequency of recurrent respiratory tract infections. Whereas knowledge on its regulatory effects in vivo has substantially advanced, the mechanisms of OM-85 sensing remain inadequately addressed.The purpose of this study was to investigate the transptomic profile of human mo-DCs after ex vivo stimulation with OM-85 at determine to what extent OM-85-induced gene signature in different myeloid cell subsets is dependent on TLR2/TLR4 expression. We also aimed to compare the OM-85-triggered gene signature with the signatures induced by specific TLR2 or TLR4 agonists.

2024-03-11 | GSE260787 | GEO

Intranasal administration of OM-85, a bacterial lysate, alters lung transcriptional profiles and protects against experimental asthma

Project description:Background: Microbial interventions against allergic asthma have robust epidemiologic underpinnings and the potential to recalibrate disease-inducing immune responses. Oral administration of OM-85, a standardized lysate of human airways bacteria, is widely used empirically to prevent respiratory infections, and a clinical trial is testing its ability to prevent asthma in at-risk children. On the other hand, we previously showed that intra-nasal administration of products from microbe-rich farm environments abrogate experimental allergic asthma. Objectives: To investigate whether direct administration of OM-85 to the airway compartment protects against experimental allergic asthma, and to identify protective cellular and molecular mechanisms activated through this natural route. Methods: BALB/cJ mice (7-8 weeks old) sensitized and challenged with Ovalbumin received OM-85 intra-nasally, and cardinal cellular and molecular asthma phenotypes were measured. Murine lung gene expression was profiled by RNA-sequencing. Results: Airway administration of OM-85 suppressed allergic asthma and altered the transcriptome profile in unfractionated lung tissue. Conclusion We provide the first demonstration that administration of a standardized bacterial lysate to the airway compartment protects from experimental allergic asthma by engaging multiple immune pathways.

2021-10-19 | GSE167867 | GEO

Gene expression profile of human mono-derived DCs stimulated with the bacterial lysate OM-85

Project description:Gene expression profile of human mono-derived DCs stimulated with the bacterial lysate OM-85

| PRJNA1083505 | ENA

The OM-85 bacterial lysate: a new tool against SARS-CoV-2?

Project description:The emergence of SARS-CoV-2, a novel coronavirus, caused the global Coronavirus disease of 2019 (COVID-19) pandemic. Because SARS-CoV-2 mutates rapidly, vaccines that induce immune responses against viral components critical for target cell infection strongly mitigate but do not abrogate viral spread, and disease rates remain high worldwide. Complementary treatments are therefore needed to reduce the frequency and/or severity of SARS-CoV-2 infections. OM-85, a standardized lysate of 21 bacterial strains often found in the human airways, has immuno-modulatory properties and is widely used empirically in Europe, South America and Asia for the prophylaxis of recurrent upper airway infections in adults and children, with excellent safety profiles. In vitro studies from our laboratory recently demonstrated that OM-85 inhibits SARS-CoV-2 epithelial cell infection by downregulating SARS-CoV-2 receptor expression, raising the possibility that this bacterial extract might eventually complement the current COVID-19 therapeutic toolkit. Here we discuss how our results and those from other groups are fostering progress in this emerging field of research.

| S-EPMC9926922 | biostudies-literature

Intranasal administration of OM-85, a bacterial lysate, alters lung transcriptional profiles and protects against experimental asthma

Project description:Intranasal administration of OM-85, a bacterial lysate, alters lung transcriptional profiles and protects against experimental asthma

| PRJNA705359 | ENA

Clinical bronchoalveolar lavage (BAL) samples

Project description:Clinical bronchoalveolar lavage (BAL) samples Targeted loci

| PRJNA408304 | ENA

Single-cell transcriptional analysis of mouse bronchoalveolar lavage (BAL) cells

Project description:We performed high-throughput single-cell RNA sequence using mouse BAL cells to identify subpopulations of airway cells.

2023-01-21 | GSE166290 | GEO

RNA-seq analysis of human asthma bronchoalveolar lavage (BAL) cells

Project description:Next-generation sequencing of human BAL cells obtained from human patients with differing degrees of asthma in a search for variations in gene expressions.

2021-04-01 | GSE136587 | GEO

Adjuvant treatment with the bacterial lysate (OM-85) improves management of atopic dermatitis: A randomized study.

Project description:BackgroundEnvironmental factors play a major role on atopic dermatitis (AD) which shows a constant rise in prevalence in western countries over the last decades. The Hygiene Hypothesis suggesting an inverse relationship between incidence of infections and the increase in atopic diseases in these countries, is one of the working hypothesis proposed to explain this trend.ObjectiveThis study tested the efficacy and safety of oral administration of the bacterial lysate OM-85 (Broncho-Vaxom®, Broncho-Munal®, Ommunal®, Paxoral®, Vaxoral®), in the treatment of established AD in children.MethodsChildren aged 6 months to 7 years, with confirmed AD diagnosis, were randomized in a double-blind, placebo-controlled trial to receive, in addition to conventional treatment with emollients and topical corticosteroids, 3.5mg of the bacterial extract OM-85 or placebo daily for 9 months. The primary end-point was the difference between groups in the occurrence of new flares (NF) during the study period, evaluated by Hazard Ratio (HR) derived from conditional Cox proportional hazard regression models accounting for repeated events.ResultsAmong the 179 randomized children, 170 were analysed, 88 in the OM-85 and 82 in the placebo group. As expected most children in both treatment groups experienced at least 1 NF during the study period (75 (85%) patients in the OM-85 group and 72 (88%) in the placebo group). Patients treated with OM-85 as adjuvant therapy had significantly fewer and delayed NFs (HR of repeated flares = 0.80; 95% confidence interval (CI): 0.67-0.96), also when potential confounding factors, as family history of atopy and corticosteroids use, were taken into account (HR = 0.82; 95% CI: 0.69-0.98). No major side effect was reported, with comparable and good tolerability for OM-85 and placebo.ConclusionsResults show an adjuvant therapeutic effect of a well standardized bacterial lysate OM-85 on established AD.

| S-EPMC5363804 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data